top of page

Dr. Abel D. Jarell, MD, FAAD

Education & Selected Honors

 

U.S. Military Academy, West Point, NY

Bachelor of Science in Chemistry, May 1993

  • Distinguished Cadet (top 5% in class academically)

  • Superintendent’s Award (Superior Achievement in Academics, Leadership and Physical Fitness)

  • West Point Outstanding Achievement in Mathematics Recognition Award (1990)

 

Harvard Medical School, Boston, MA

Doctor of Medicine, June 1998

  • Recipient of NIH Pre-doctoral Research Fellowship

  • AMA/Glaxo Welcome National Achievement/Leadership Delegate

 

Post-Graduation Education

Internship – General Surgery, 7/98 – 6/99

University of Washington, Department of Surgery, Seattle, WA

 

Residency – Dermatology, 7/06 – 6/09

Harvard Medical School, Department of Dermatology, Boston, MA

Chief Resident, 7/08 – 6/09

Fellowship – Dermatopathology, 7/09 – 7/10

University of California (UCSF), Department of Dermatopathology, San Francisco, CA

 

Board Certifications 
 

Dermatology: American Board of Dermatology, 2009, Recertified 2019 

Dermatopathology: American Board of Dermatology, 2010, Recertified 2019

 

Medical Licenses
 

Maine – current, active, unrestricted (MD22699) 

Maryland – current, active, unrestricted (D0073683)

Massachusetts – current, active, unrestricted (235410)

New Hampshire – current, active, unrestricted (15251)

Selected Leadership Positions
 

4/2017 – 4/2020    President, New Hampshire Society for Dermatology                                  

4/2016 – 4/2017     Secretary, New Hampshire Society for Dermatology                         

3/2018 – present    Voting Member, Am. Acad. of Dermatology Healthcare & Finance Committee    

3/2016 – present    Voting Member, Am. Acad. of Dermatology, Leadership Committee

 

Experience & Positions Held
 

6/2019 – present     Medical Director, Chief Investigator

                ALLCUTIS Research, Inc., Center for Understanding Therapeutics in Skin

            Portsmouth, NH

3/2016 – present     Principal Investigator 

            ActivMed Practices & Research, Inc

            Portsmouth, NH 

3/2015 – present    Dermatologist & Dermatopathologist

            Northeast Dermatology Associates (NEDA)

            Portsmouth, Conway & Dover, NH and Portland, ME 

 

7/2010 – 1/2015    Assistant Professor of Dermatology & Dermatopathology

            Walter Reed National Military Medical Center

            Uniformed Services University of the Health Sciences

            Bethesda, MD

            

  • Chief, Dermatopathology, Dermatology Section, Department of Medicine

  • Director, Walter Reed & Murtha Cancer Center Melanoma and Pigmented Lesion Clinic

  • Associate Program Director, Walter Reed Dermatopathology Fellowship

  • Cancer Liaison Physician for Walter Reed to the American College of Surgeons

  • Head of the Dermatology visitor, medical student and intern/resident rotators

  • Scientific Review Committee Member, Walter Reed Bethesda

  • Quality Assurance Officer, Department of Dermatology

  • Winner of 1st Place, Association of Military Dermatologists Staff Research Award (2012)

  • Winner of 3rd Place, Association of Military Dermatologists Staff Research Award (2014)

  • Delegate to the American Academy of Dermatology Academic Dermatology Leadership Program (ADLP)


8/2011 – 2/2015        Staff Dermatologist & Dermatopathologist

        Saco River Medical Group

        Conway, NH

Work as dermatologist and dermatopathologist in under-served White Mountains / Mt. Washington Valley region of NH. Perform all duties of general dermatologist and dermatopathologist, approximately 2 full days per month.

1/2011 – 6/2011    Squadron Surgeon & General Medical Officer 

                2nd Cavalry Regiment / 4th Squadron

Kandahar Province and Arghandab River Valley, Afghanistan 

Squadron staff officer, consultant to the commander. Deployed to Afghanistan in support of Operation Enduring Freedom. Duties include overall responsibility for health and welfare of squadron and all forward operating base personnel (approx. 1,100).

 

7/2003 – 8/2004    Brigade Surgeon & General Medical Officer

            3rd Brigade/1st Armor Division

            Ft. Riley, KS

 

8/2004 – 5/2006    Brigade Staff Officer, Consultant to Commander

            1st Brigade/1st Infantry Division

            Ft. Riley, KS

            Deployed to Iraq in support of Operation Iraqi Freedom. Duties include overall                 responsibility for health and welfare of Brigade Combat Team (approx. 4,500 soldiers),             primary care medical management, preventive medicine, supervision of five physician             assistants and combat readiness for brigade. Senior medical officer in combat theatre of             operations, overseeing additional six physicians. Supervise technical training of medical             personnel. Monitor and supervise aeromedical and ground ambulance evacuation                 (MEDEVAC). Recipient of the Combat Medical Badge for performance of medical             duties while under fire during combat operations. Recipient of the Meritorious Service             Medal and nominated for the Bronze Star Medal.

 

1/2001 – 7/2002    Graduate Student & Research Assistant 

            Neurosurgery / Neurology National Capital Neurotrauma Research Laboratory

            Bethesda, MD 

                Laboratory of Drs. James Ecklund and Geoffrey Ling. Conducted research directed                 toward the elucidation of cellular and molecular mechanisms involved in traumatic                 brain injury.

 

6/1999 – 1/2001        Post-Doctoral Research Fellow 

                University of Washington and Children’s Hospital, Dept. of Neurological Surgery    

                    Seattle, WA 

    Laboratories of Drs. Richard S. Morrison and Michael Bobola. Focus of Morrison lab is on elucidating mechanisms, modulators and effectors involved in neuronal cell death especially in oncology and programmed cell death. Investigated involvement of new gene and protein expression in variety of cell lines as well as in tumor operative specimens and modulated expression of novel gene/protein to study effects. Conducted seminal studies in novel cell cycle regulator pescadillo (gene and protein) and its involvement in tumor malignancy. Also, using gene transfection methods, investigated involvement of BAX and BAD in neuronal cell death. Focus of Bobola laboratory is pediatric neuro-oncology. Obtained pediatric brain tumor specimens and purified RNA for RT-PCR amplification of cDNA to study novel gene expression.

3/1994 – 4/1998     NIH Predoctoral Research Assistant 

                Children’s Hospital & Harvard Medical School Program in Neuroscience

                Boston, MA 

Laboratory of Dr. Jeffrey D. Macklis, Department of Neurology, Children’s Hospital. Primary focus of lab is on neocortical development, cellular differentiation, and neuronal transplantation. Designed and conducted experiments in conjunction with Macklis and others on C57Bl/6J mice to determine spatial and temporal characteristics of microglia in model of selective neuronal degeneration. Provided evidence for programmed cell death in the same model demonstrating the necessity for both new protein synthesis and endonuclease activation. Work presented at 1996 Society for Neuroscience Annual Meeting, 1995 & 1997 Soma Weiss Research Assemblies, and 1997 NIH Scientists, Tools & Research for the 21st Century Conference.                

 

Principal Investigator Clinical Research Trial Experience         

 

2015
 

Eli Lilly            Phase 3, Moderate to Severe Plaque Psoriasis

Braintree            Phase 3, Topical Treatment for Moderate to Severe Facial Acne

Cutanea Life Sciences        Phase 2, Topical Gel for Females with Moderate to Severe Facial Acne

Dermira            Phase 3, Moderate to Severe Plaque Psoriasis, Certolizumab Pegol

Eli Lilly            Phase 3, Moderate to Severe Plaque Psoriasis, SC injection

Regeneron            Phase 3, Moderate to Severe Atopic Dermatitis, Dupilumab SC injection

 

2016
 

Par Pharmaceuticals        Phase 3, Mild to Moderate Atopic Dermatitis

Sol-Gel            Phase 2, Topical Treatment for Facial Acne 

 

2017
 

Athenex            Phase 3, Topical Treatment for Actinic Keratosis

Cellceutix            Phase 3, Moderate to Severe Plaque Psoriasis, Oral Treatment

Cutanea Life Sciences        Phase 3, Common Warts

Foamix            Phase 3, Moderate to Severe Acne

Incyte Pharmaceuticals    Phase 2, Vitiligo, Topical Treatment

RXi Pharmaceuticals        Phase 2, Common Warts, Samcyprone Ointment

UCB                Phase 3, Moderate to Severe Plaque Psoriasis, SC injection (PS0009)

 

2018
 

AbbVie, Inc.            Phase 3, Moderate to Severe Atopic Dermatitis in Adolescents & Adults

Asana Biosciences        Phase 2, Moderate to Severe Atopic Dermatitis, Oral Treatment

Incyte Pharmaceuticals    Phase 3, Atopic Dermatitis, Topical Treatment

Trevi Pharmaceuticals        Phase 2b/3, Prurigo Nodularis, ER Nalbuphine

UCB                Phase 3, Moderate to Severe Plaque Psoriasis, SC injection (PS0013)

UCB                Phase 3, Moderate to Severe Plaque Psoriasis, SC injection (PS0014

UCB                Phase 3, Moderate to Severe Plaque Psoriasis, SC injection (PS0015)

Asana Biosciences        Phase 2b, Moderate to Severe Atopic Dermatitis, Open-Label Extension 

Bristol Myers Squibb        Phase 3, Moderate to Severe Plaque Psoriasis, SC injection

Celgene Corporation        Phase 3, Moderate to Severe Genital Psoriasis, Oral Treatment 

Dermira            Phase 2b, Moderate to Severe Atopic Dermatitis, Lebrikizumab

Eli Lilly            Phase 4, Moderate to Severe Plaque Psoriasis, SC injection

 

2019
 

AbbVie, Inc.            Phase 3, Risankizumab Autoinjector for Psoriasis

Amgen                                    Phase 3, Moderate to Severe Plaque Psoriasis, SC injection

Arcutis    , Inc.            Phase 3, Mild to Moderate Plaque Psoriasis, Topical Treatment

Asana Biosciences        Phase 2, Moderate to Severe Hand Eczema

Concert Pharmaceuticals    Phase 2, Moderate to Severe Alopecia Areata

Concert Pharmaceuticals    Phase 2, Moderate to Severe Alopecia Areata, Open-Label Extension

Dermira            Phase 3, Moderate to Severe Atopic Dermatitis, Lebrikizumab

Dermira            Phase 3, Moderate to Severe Atopic Dermatitis, Lebrikizumab/Topical Combo

Dermira                                   Phase 3, Moderate to Severe Atopic Dermatitis Adolescents, Lebrikizumab

Eli Lilly            Phase 2/3, Moderate to Severe Alopecia Areata, Baricitinib

Eli Lilly            Phase 1, Atopic Dermatitis, SC injection

Eli Lilly             Phase 1, Psoriasis, SC injection

Galderma            Phase 3b, Topical Treatment for Moderate to Severe Facial & Truncal Acne

Galderma            Phase 3, Topical Treatment for Actinic Keratosis

Novan, Inc.            Phase 3, Topical Treatment for Molluscum Contagiosum

UCB                Phase 3, Moderate to Severe Plaque Psoriasis, Adolescent & Pediatric, Cimzia

UCB                                        Phase 3, Moderate to Severe Hidradenitis Suppurativa, SC injection 

 

2020
 

AoBiome Therapeutics           Phase 2, Topical Spray for Pruritis in Adults with a History of Atopic Dermatitis

Arcutis, Inc.                            Phase 3, Mild to Moderate Plaque Psoriasis, Topical Treatment, Open-Label Ext

Arcutis, Inc.                            Phase 2b, Scalp and Body Psoriasis in Adolescents and Adults, Topical Treatment

Arcutis, Inc.                            Phase 2, Topical Treatment for Seborrheic Dermatitis

AstraZeneca                            Phase 2, Moderate to Severe Atopic Dermatitis, Benralizumab

Bellus Health                          Phase 2, Oral Treatment for Chronic Pruritus in Adults with Atopic Dermatitis

Bristol Myers Squibb             Phase 3b, Moderate to Severe Plaque Psoriasis, SC injection, Extension Study

Dermira                    Phase 3, Moderate to Severe Atopic Dermatitis, Lebrikizumab Open-Label Ext

Eli Lilly                                  Phase 2, Moderate to Severe Hidradenitis Suppurativa, SC injection 

Galderma                                Phase 3, Topical Treatment for Actinic Keratosis, Open-Label Extension

Galderma                                Phase 2, Atopic Dermatitis in Adolescents and Adults, SC injection

Nimbus Lakshmi, Inc.            Phase 1, Oral Treatment for Moderate to Severe Plaque Psoriasis

 

2021
 

Amgen                                     Phase 3, Moderate to Severe Plaque Psoriasis, SC injection

AnaptysBio                             Phase 2, Hidradenitis Suppurativa, SC injection

AnaptysBio                             Phase 2, Acne Vulgaris, SC injection

UCB                                        Phase 3, Moderate to Severe Hidradenitis Suppurativa, SC injection, Extension

Publications 

Original Aticles and Case Reports

 

  • Gottlieb A, Gooderham M, Jarell A (2021) Absolute improvements in BSA and PASI at week 12 associate with improvements in nail psoriasis, itch, and quality of life at week 24 in treatment of moderate-to-severe psoriasis. Journal of Drugs in Dermatology. In press.

  • Jarell AD, Skenderis B, Dillon LD, Dillon K, Martin B, Quick AP, Siegal JJ, Rackley B, Cook RW (2021) The 31-Gene Expression Profile stratifies recurrence and metastasis risk in patients with cutaneous melanoma. In Press

  • Dillon LD, McPhee M, Davidson RS, Quick AP, Martin B, Covington KR, Zolochevska O, Cook RW, Vetto JT, Jarell AD, Fleming MD (2021) Expanded evidence that the 31-Gene Expression Profile test provides clinical utility for melanoma management in a multicenter study. In press

  • Porter C, Riddle S, Jarell AD (2020) A first in human clinical trial assessing the safety and immunogenicity of transcutaneously delivered enterotoxigenic Escherichia coli fimbrial tip adhesin with or without heat-labile enterotoxin with mutation R192G. (IN PRESS)  Vaccine. 

  • Gutierrez R, Porter CK, Jarell AD, et al. (2020) A grading system for local skin reactions developed for clinical trials of an intradermal and transcutaneous ETEC vaccine. Vaccine. 6;38(21):3773-3779.

  • Blauvelt A, Papp K, Gottlieb A, Jarell A, Reich K, Maari C, Gordon KB, Ferris LK, Langley RG, Tada Y, Lima RG, Elmaraghy H, Gallo G, Renda L, Park SY, Burge R, Bagel J; IXORA-R Study Group.  A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial. (2020) Br J Dermatol. 2020 Jun;182(6):1348-1358.

  • Dillon, LD, Gadzia JE, Jarell AD, et al. (2018) Prospective, Multicenter Clinical Impact Evaluation of a 31-Gene Expression Profile Test for Management of Melanoma Patients. Skin. 2(2). 

  • Wang B, Jarell AD, Bingham JL, and Bonavia GH. (2015) PET/CT Imaging of squamoid eccrine ductal carcinoma. Clin Nucl Med. 2015 Apr;40(4):322-4.

  • Hoverson K, Jarell AD, Wohltmann W. (2017) Lupus erythematosus tumidus of the scalp masquerading as alopecia areata.  Cutis. 2017 February;99(2): E22-E24.

  • Morgan MK, Whitman TJ, Cohen JI, Mitchum MD, Jarell AD, Burgess TH. (2014) A patient with fever and rash. Clin Infec Dis. 2014 Jul 1;59(1):95, 136-7.

  • Oganesyan G, Jarell AD, Srivastava M, Jiang SI. (2013) Efficacy and complication rates of full-thickness skin graft repair of lower extremity wounds after Mohs micrographic surgery.  Dermatol Surg. Sep;39(9):1334-9.

  • Jarell AD and McCalmont TH.  (2012).  Granular cell angiosarcoma.  J Cutan Pathol. May;39(5):476-8.

  • Jarell AD and Mully TM. (2012) Basal cell carcinoma of the ear is more likely to be of an aggressive phenotype in both men and women.  Journal of the American Academy of Dermatology. May;66(5):780-4.

  • Jarell AD, Dans MJ, Elston DM, et al. (2011) Gnathostomiasis in a patient who frequently consumes sushi. Am J Dermatopathol.  Dec:33(8):91 - 93.

  • Konnikov N, Avram M, Jarell AD, Tannous Z. (2011) Pulsed dye laser as a novel non-surgical treatment for basal cell carcinomas: response and follow up 12-21 months after treatment.  Lasers Surg Med. Feb;43(2):72-8.

  • Morgan EA, Henrich TJ, Jarell, AD, Velazquez EF, et al.  (2010) Infectious granulomatous dermatitis associated with Rothia mucilaginosa bacteremia:  a case report.  Am J Dermpathol.  32(2):175 – 9

  • Tucker JD, Shah S, Jarell AD, Tsai KY, Zembowicz A, Kroshinsky D (2009) Lues maligna in early HIV infection. Case report and review of the literature.  Sex Transm Dis.  36(8):512 – 4.

  • Jarell AD, Hall MA, Sperling LC (2007) Uncombable Hair Syndrome. Pediatric Dermatology. 2007 Jul- Aug;24(4):436-438.

  • Jarell AD, Hall MA (2007) Swelling of the Right Ear.  Am Fam Physician. 1;75(9):1379-1380.

  • Kinoshita Y, Jarell AD, Morrison RS, et al. (2001) Pescadillo, A Novel Cell Cycle Regulatory Protein Abnormally Expressed in Malignant Cells.  J Biol Chem. 276(9):6656-6665.

  • Foltz, GD, Jarell AD, Schuster JS, Matsumura M, Farrell L, Nelson P, Silbergeld DL (2000) Identification and Characterization of VASP, a Motility-related Gene with Aberrant Expression in Glioblastoma.  Neurosurgery. 47(2):518.

  • Kuntz C IV, Mirza SK, Jarell AD, Chapman JR, Shaffrey CI, Newell DW (2000) Type II Odontoid Fractures in the Elderly:  Early Failure of Nonsurgical Treatment.  Neurosurgical Focus 8(6):7 2000.

 

Reviews

 

  • Jarell AD, Kimball AB (2009 with updates in annually, most recent 2020) Rosacea.  Brit Med J.  Online publication.

  • Jarell AD, Lawrence D, Tsao H (2007) The RAS/mitogen activated protein (MAP) kinase pathway in melanoma biology and therapeutics.  Biologics. 1(4):407-414.

  • Temkin NR, Jarell AD, Anderson GD (2001) Antiepileptogenic Agents:  How Close are We?  Drugs. 61(8):1045-1055.

  • Soltesz EG, Jarell AD, Black PM, et al.  (1999) Radiation Therapy for Gliomas.  Crit Rev. Neurosurg. 9:376-386.

                                                    

Book Chapters

 

  • Jepperson S and Jarell AD (2014) Ticks. Chapter in: Manual of Dermatologic Therapeutics, 8th Ed. Eds. Arndt, Hsu, Alam, et al. Lippincott.

  • Jepperson S and Jarell AD (2014) Sunburn. Chapter in: Manual of Dermatologic Therapeutics, 8th Ed. Eds. Arndt, Hsu, Alam, et al. Lippincott.

  • Kim D and Jarell AD (2014) Burns.  Chapter in:  Manual of Dermatologic Therapeutics, 8th Ed.  Eds. Arndt, Hsu, Alam, et al. Lippincott.

  • Buikema K and Jarell AD (2014) Dermatophytosis. Chapter in: Manual of Dermatologic Therapeutics, 8th Ed. Eds.  Arndt, Hsu, Alam, et al. Lippincott.

  • Jarell, AD (2012) Nodular fasciitis. Chapter in: Horvai: Bone and Soft Tissue Pathology. Ed. A. Horvai. Elsevier. Philadelphia. 194-196.

  • Jarell, AD (2012) Proliferative myositis and proliferative fasciitis. Chapter in: Horvai: Bone and Soft Tissue Pathology. Ed. A. Horvai.  Elsevier.  Philadelphia. 197-198.

  • Jarell, AD (2012) Ischemic fasciitis. Chapter in: Horvai: Bone and Soft Tissue Pathology. Ed. A. Horvai. Elsevier. Philadelphia. 199-200.

  • Jarell, AD (2012) Postoperative spindle cell nodule. Chapter in: Horvai: Bone and Soft Tissue Pathology.  Ed. A.  Horvai.  Elsevier.  Philadelphia. 201-202.

  • Jarell, AD (2012) Necrotizing fasciitis. Chapter in: Horvai: Bone and Soft Tissue Pathology. Ed. A. Horvai. Elsevier. Philadelphia. 203-204.

  • Jarell, AD (2012) Elastofibroma. Chapter in: Horvai: Bone and Soft Tissue Pathology. Ed. A. Horvai. Elsevier. Philadelphia. 205-206.

  • Jarell, AD (2012) Desmoplastic fibroblastoma. Chapter in: Horvai: Bone and Soft Tissue Pathology. Ed. A. Horvai. Elsevier.  Philadelphia. 207-208.

  • Jarell, AD (2012) Hypertrophic scar. Chapter in: Horvai: Bone and Soft Tissue Pathology. Ed. A. Horvai. Elsevier. Philadelphia. 209-210.

  • Jarell, AD (2012) Keloid. Chapter in: Horvai: Bone and Soft Tissue Pathology. Ed. A. Horvai. Elsevier. Philadelphia. 211.

  • Jarell, AD (2012) Fibrous hamartoma of infancy. Chapter in: Horvai: Bone and Soft Tissue Pathology. Ed. A. Horvai. Elsevier.  Philadelphia. 212-213.

  • Jarell, AD (2012) Gardner fibroma. Chapter in: Horvai: Bone and Soft Tissue Pathology. Ed. A. Horvai. Elsevier. Philadelphia. 214-215.

  • Jarell, AD (2012) Nuchal fibroma. Chapter in: Horvai: Bone and Soft Tissue Pathology. Ed. A. Horvai. Elsevier. Philadelphia. 216.

  • Jarell, AD (2012) Fibromatosis colli. Chapter in: Horvai: Bone and Soft Tissue Pathology. Ed. A. Horvai. Elsevier. Philadelphia. 217-218.

  • Jarell, AD (2012) Calcifying aponeurotic fibroma. Chapter in: Horvai: Bone and Soft Tissue Pathology. Ed. A. Horvai. Elsevier.  Philadelphia. 219-220.

  • Jarell, AD (2012) Fibroma of tendon sheath. Chapter in: Horvai: Bone and Soft Tissue Pathology. Ed. A. Horvai. Elsevier.  Philadelphia. 221-222.

  • Jarell, AD (2012) Superficial fibromatosis. Chapter in: Horvai: Bone and Soft Tissue Pathology.  Ed. A. Horvai.  Elsevier.  Philadelphia. 223-224.

  • Jarell, AD (2012) Deep fibromatosis. Chapter in: Horvai: Bone and Soft Tissue Pathology. Ed. A. Horvai. Elsevier. Philadelphia. 225-227.

  • Jarell, AD (2012) Inclusion-body fibroma. Chapter in: Horvai: Bone and Soft Tissue Pathology.  Ed. A. Horvai.  Elsevier.  Philadelphia. 228-229

  • Jarell, AD (2012) IgG4-related sclerosing disease. Chapter in: Horvai: Bone and Soft Tissue Pathology. Ed. A. Horvai. Elsevier.  Philadelphia. 230-231.

  • Jarell, AD (2012) Giant cell fibroblastoma. Chapter in: Horvai: Bone and Soft Tissue Pathology. Ed. A. Horvai.  Elsevier.  Philadelphia. 264-265.

  • Jarell AD, Schalock PS (2010) Procedures in Dermatologic Diagnosis and Therapy. Chapter in: Primary Care Dermatology.  Eds. PC Schalock, J Hsu, and K Arndt.  Philadelphia:  Lipincott Williams & Wilkins.  20 – 27.

  • Jarell AD, Ecklund JM, Ling GS (2001) Traumatic Brain Injury. Chapter in: Combat Medicine. Executive Ed. GC Tsokos.  New York:  Humana Press. 351-370.

  • Morrison RS, Jarell AD, Schuster JM (2003) Growth Factors and Brain Tumors. Chapter in: Youman’s Neurological Surgery.  5th Ed.  Executive Ed. HR Winn.  Philadelphia:  Saunders. 725-738.

  • Riechers RG, Jarell AD, Ling GS (2004) Infections of the Central Nervous System. Chapter in: Critical Care Neurology and Neurosurgery.  Executive Ed. JI Suarez.  New York:  Humana Press. 515-532.

 

Audio Publications and Interviews
 

  • Jarell AD interviewed by DermTube. Shedding Light on the Darkness. DermTube video interview. Publication of the American Academy of Dermatology. July 2018. 

  • Jarell AD interviewed by DermTube. Build a Better Relationship with your Dermatopathologist. DermTube video interview (https://dermtube.com/series/meeting-coverage-orlando-2017-mar/build-a-better-relationship-with-your-dermatopathologist/). Publication of the American Academy of Dermatology. March 2017. 

  • Jarell AD interviewed by Kouroush AS. Help Your Dermatopathologist Work Smarter for You. Dialogues in Dermatology.  Publication of the American Academy of Dermatology.  April 2015.

Abstracts and Presentations

 

  • Jarell AD, Smith S, Gallo G, et al. (2021) Ixekizumab Provides More Durable Improvements in Skin Clearance, Itch, and Quality of Life than Guselkumab in Patients with Moderate-to-Severe Psoriasis: 24-week Results from IXORA-R. Congress of Clinical Rheumatology West, Sept 2021

  • Jarell AD, Smith S, Gallo G, et al. (2021) Ixekizumab Provides More Durable Improvements in Skin Clearance, Itch, and Quality of Life than Guselkumab in Patients with Moderate-to-Severe Psoriasis: 24-week Results from IXORA-R. AAD—VMX 2021

  • Jarell AD (2020) Help Your Dermatopathologist Work Smarter for You. Presented at the American Academy of Dermatology Meeting, Denver, 3/20.

  • Andrew Blauvelt A, Kempers S, Forman S, Lain E, Bruce S, Ablon G, Jarell A, Bukhalo M, Liberman R, and Fang J. Tirbanibulin, a Novel Inhibitor of Tubulin Polymerisation and Src Kinase Signalling, for Actinic Keratosis: Results from two Phase III Studies. Eur Academy of Dermatology 2020.

  • Jarell AD (2018) Shedding Light on the Darkness—Pigmented Lesions. Presented at the American Academy of Dermatology Meeting, Chicago, 7/18.

  • Jarell AD (2018) Thin and Early Stage Melanoma. Presented at the Society for Dermatology Physician Assistants Annual Meeting by invitation, Seattle, WA.

  • Jarell AD (2018) Locally Advanced and Metastatic Melanoma. Presented at the Society for Dermatology Physician Assistants Annual Meeting by invitation, Seattle, WA.

  • Jarell AD (2017) Shedding Light on the Blackness—Pigmented Lesions.  Presented at the American Academy of Dermatology Meeting, New York, 7/17.

  • Jarell AD (2017) Help Your Dermatopathologist Work Smarter for You. Presented at the American Academy of Dermatology Meeting, Orlando, 3/17.

  • Brady SP and Jarell AD (2015) Strappy Cells: A distinctive histological feature of and useful diagnostic clue in chondrodermatitis nodularis helicis. Am Society of Dermatopathoology Meeting, San Francicso, 10/15.

  • Jarell AD (2014) Help your dermatopathologist work smarter for you. Podium-presented at American Academy of Dermatology Meeting, Chicago, 8/14.

  • Gutierrez R, Riddle M, Porter C, Maciel M Turiansky G, Jarell, A, Savarino S. (2013) Development and use of vaccine site grading scale for local vaccine site reactions after transcutaneous and intradermal vaccination with adhesin based ETEC vaccine candidates. Presented at the Vaccines for Enteric Diseases (VED) 2013 - Seventh International Conference, Bangkok, Thailand, 2013.

  • Bhatia A, Hsu, J, Jarell AD, et al. (2012) The Chief Academy – Building a foundation for successful chief residents Our 5-year experience & planning for the future. Presented at the Program Directors Annual Meeting, Chicago, 2012.

  • Childs JC and Jarell AD. (2012). Papillary thyroid carcinoma metastatic to the skin. Presented at National Capital Consortium Research Day Symposium, 9 April 2012.

  • Jarell AD and Mully TM. (2010) Basal cell carcinoma of the ear is more likely to be of an aggressive phenotype in both men and women.  Am Soc Dermatopathol. 2010.

  • Jarell AD, Dans MJ, Elston DM, et al. (2010) Gnathostomiasis in a patient who frequently consumes sushi. International Soc Dermatopathol. 2010.

  • Jarell AD and McCalmont TH.  (2010) Granular cell angiosarcoma:  A rarity.  Am Soc Dermatopathol. 2009.

  • Konnikov N, Jarell AD, Tannous Z (2009) Response and recurrence rates of basal cell carcinomas treated with pulsed dye laser.  American Society for Laser Medicine and Surgery Annual Meeting, 2009.

  • Jarell AD, Srivastava M, Jiang B. (2007) Full thickness skin graft (FTSG) repair for lower extremity (below knee) tumors treated by Mohs Micrographic Surgery (MMS).  Mohs College Annual Meeting, 2007.

  • Ling GSF, Riechers RG, Krishna PM, Blanchard J, Rosner M, Jarell AD, et al. (2002) Diagnosis of compartment syndrome using a microwave-based detector.  Proceedings of SPIE -- Volume 4744.

  • Jarell AD, Agoston DV, Ling GSF (2001) Expression of Pescadillo, a Novel Cell Cycle Regulator, in the Injured Rat Brain.  USUHS Neuroscience Research Day 2001. Abst.

  • Jarell AD, Foltz GD, Kinoshita Y, Morrison RS (2001) Pescadillo: Characterization of a Novel Cell Cycle Regulator Abnormally Expressed in Human Tumors. Congress of Neurological Surgeons Annual Meeting, 2001. Abst.  (Recipient of CNS Overall 2nd Prize for Outstanding presentation).

  • Foltz GD, Jarell AD, Schuster J, Matsamura M, et al. (2000) Identification and Characterization of VASP, a Motility- Related Gene with Aberrant Expression in Glioblastoma, using cDNA Microarrays. Congress of Neurological Surgeons Annual Meeting, 2000. Abst.

  • Kuntz C IV, Jarell AD, Chapman JR, Shaffrey CI, Newell DW (1999) Odontoid Type 2 Fractures in the Elderly: Operative vs. Nonoperative Treatment.  Assoc. of American Neurological Surgeons Annual Meeting, 2000. Abst.

  • Jaramillo AD, Leavitt BR, Macklis JD (1997) Targeted Photolytic Apoptosis in Neuronal PC12 Cells is Dependent on New Protein Synthesis and Intrinsic Endonuclease Activity.  NIH Scientists, Tools, & Research for the 21st Century Abst.

  • Jaramillo AD, Leavitt BR, Macklis JD (1996) Targeted Photolytic Apoptosis in PC12 Cells is Dependent on Intrinsic Endonuclease Activity.  Soc. Neurosci. Abst. 679.13.

  • Jaramillo AD, Macklis JD (1995) Spatial and Temporal Characteristics of Microglia in Model of Selective Neuronal Degeneration.  Soma Weiss Abst.

  • Jaramillo AD, Sloop J (1993) Effect of Pyrazole Moiety on COS, CHO, CRL, and VERO Cell Lines. E. College Science Conf.

bottom of page